Printer Friendly

GERMAN STUDY SHOWS PROMISING RESULTS FOR IMMUNOMEDICS' INFECTIOUS DISEASE IMAGING AGENT

 GERMAN STUDY SHOWS PROMISING RESULTS FOR
 IMMUNOMEDICS' INFECTIOUS DISEASE IMAGING AGENT
 MORRIS PLAINS, N.J., June 11 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) announced today, at the annual Society of Nuclear Medicine Meeting, results of a 10-patient study of the company's infectious disease imaging agent, ImmuRAID(TM)-MN3, completed in Erlangen, Germany.
 The study results found that doses as small as a half-milligram could detect sites of bone, abdominal, or sinus infections as early as one hour after injection. It was also reported that the Immunomedics product gave lower radiation exposure to the patients than is the case for the standard method of labeling white blood cells with indium. In eight of the 10 patients analyzed one month later, no allergic antibody responses to the mouse protein (HAMA) were found.
 Immunomedics' product, an antibody fragment, is reactive with certain white blood cells that accumulate in sites of infection and is labeled in a simple and rapid method with technetium-99m, and then injected into the patient for scanning with a conventional nuclear medicine camera. The standard method involves removing a patient's blood, isolating the white blood cells, labeling the white blood cells with indium-111 or technetium-99m, reinjecting the radioactive blood cells, and then scanning the patient 24-28 hours later. Thus, with the Immunomedics product, no handling of patient's blood is needed, and the attendant risks of infection of laboratory and medical personnel is avoided.
 "These independent findings directed by Professor W. Becker corroborate clinical results obtained in the United States and show the general applicability and simplicity of our imaging agent," commented Dr. Carl Pinsky, vice president, medical affairs. "Current clinical trial results lead us to believe that this product will aid in the rapid detection and diagnosis of a diverse array of infectious and inflammatory lesions which require early intervention. We are planning our Phase III, pivotal, clinical trial, to be implemented in the next few months," Pinsky added.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
 -0- 6/11/92
 /CONTACT: Amy Factor of Immunomedics, 201-605-8200/
 (IMMU) CO: Immunomedics Inc. ST: New Jersey IN: MTC SU:


TS-CK -- NY038 -- 9177 06/11/92 10:50 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 11, 1992
Words:402
Previous Article:BALL PACKAGING PRODUCTS CANADA PLANS CLOSURE OF MONTREAL METAL CAN MANUFACTURING FACILITY
Next Article:DETROIT WATER & SEWERAGE DEPARTMENT ISSUES $269,440,000 IN REVENUE BONDS
Topics:


Related Articles
IMMUNOMEDICS REPORTS NEW CLINICAL RESULTS OF INFECTIOUS DISEASE IMAGING AGENT
IMMUNOMEDICS REPORTS VIRTUALLY NO ALLERGIC REACTIONS IN PATIENTS IMAGED WITH ANTIBODY AGENT, IMMURAID-CEA
IMMUNOMEDICS ANNOUNCES POSITIVE CLINICAL RESULTS
IMMUNOMEDICS RECEIVES FDA APPROVABLE LETTER FOR CEA-SCAN
IMMUNOMEDICS AWARDED ORPHAN DRUG DESIGNATION FOR CEA-SCAN IN THE DIAGNOSIS OF MEDULLARY THYROID CANCER
IMMUNOMEDICS' RADIOLABELED ANTIBODY SHOWS ACTIVITY IN OVARIAN CANCER
IMMUNOMEDICS REPORTS PROGRESS WITH CANCER THERAPEUTIC PROGRAM; EIGHT ABSTRACTS PRESENTED AT THE SOCIETY OF NUCLEAR MEDICINE CONFERENCE
IMMUNOMEDICS IS GRANTED TWO U.S. PATENTS
Immunomedics Patents New Diagnostic and Therapeutic Agents
Imaging Specialists Hear Report on Painless, Nonsurgical 'Nuclear Biopsies' for Women with Suspicious Mammograms

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters